Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents

2021 ◽  
Author(s):  
Elisabetta Degasperi ◽  
Riccardo Perbellini ◽  
Roberta D’Ambrosio ◽  
Sara Colonia Uceda Renteria ◽  
Ferruccio Ceriotti ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Vitamin K ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Caucasian Patients ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Role of Serum Nitric Oxide in Prediction of Hepatocellular Carcinoma in Hepatitis C Patients Treated with Direct - Acting Antiviral Agents

2020 ◽  
Vol 05 (04) ◽  
Author(s):  
Basha OM ◽  
Elsadek HM ◽  
Shokry MM ◽  
Elsaid HH ◽  
Farag AA
Keyword(s):  
Nitric Oxide ◽  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Impact of direct-acting antiviral agents-induced SVR on the long-term burden of hepatocellular carcinoma in chronic hepatitis C cirrhosis.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 230-230
Author(s):  
Prowpanga Udompap ◽  
Ajitha Mannalithara ◽  
Donghee Kim ◽  
W. Ray Kim
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Antiviral Agents ◽  
Sensitivity Analyses ◽  
Old Patients ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
The Impact ◽  
Direct Acting Antiviral Agents

230 Background: Sustained virological response (SVR) has been associated with decreased morbidity and mortality from hepatitis C virus (HCV) infection. Data are sparse, however, about the long-term benefits of direct-acting antiviral agents (DAAs) in terms of risk reduction for hepatocellular carcinoma (HCC). We estimate the impact of SVR on the HCC incidence in the DAA era when SVR is achieved nearly universally even in patients with advanced fibrosis and cirrhosis. Methods: We constructed a Markovian model of 50-year-old patients with compensated HCV cirrhosis (n=1,000) to model the incidence of HCC over 20-years of follow-up. We compared 2 cohorts: 1) SVR following DAA therapy and 2) no SVR (natural history). In the latter, HCC would develop at an annual rate of 4.2% and patients would die as a result of end stage liver disease (ESLD) according to their MELD (=6 at baseline). In the former, MELD score would not increase, the HCC risk would decrease and, in some patients, cirrhosis would regress. Results: The table summarizes the 20-year outcome in the two cohorts. In the cohort without SVR, HCC would occur in 33% and 63% would die of ESLD. In the SVR cohort, the proportion of HCC would increase to 37% as the number of subjects at HCC risk would increase, as a result of a dramatic reduction in deaths from ESLD. In the univariate sensitivity analyses, the cumulative HCC incidence was mainly influenced by the rate at which the risk of HCC is decreased after SVR, followed by the change in cirrhosis regression rate. Conclusions: Although HCC risk would decrease after SVR in a given individual patient with cirrhosis, on the population level, highly effective DAA therapy may lead to a paradoxical increase in the burden of HCC. These data underscore the important of (1) HCC surveillance in patients with cirrhosis even after SVR and (2) DAA intervention before cirrhosis develops. [Table: see text]

Hepatocellular Carcinoma Occurrence in Non-Cirrhotic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1592
Author(s):  
Amal Hejab ◽  
Aula Ramo ◽  
Bradley Greib ◽  
Jonathan Mansour ◽  
Reena Salgia
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents
Sign in / Sign up

Export Citation Format

Share Document